Deals in Depth: December 2009
Astellas will be developing Ambit's FLT3 kinase blockers in the month's largest deal at $390 million. Sanofi-Aventis' move into the US OTC market was evident in its acquisition of Chattem for $2.1 billion. In one of the five biggest medical device acquisitions of 2009, Ethicon bought sinus surgical device company Acclarent for $785 million. Financing for biopharma companies increased dramatically to over $2 billion, most of which came from three $400 million-plus FOPOs. Device fundraising was down slightly in December, although diabetes management firm Intuity Medical impressed with its $64 million Series D round.
You may also be interested in...
Having kept out of the race to develop a vaccine, Novartis has joined efforts with a collaboration using the AAV gene therapy vector.
Philips has added a Clinical Trials Accelerator functionality to the cloud-based HealthSuite digital platform, underlining its role in securely managing and collecting device and personal data for use by third-party clients seeking to build health care solutions.
Bavencio’s Survival Benefit Confirmed In Front-Line Maintenance Therapy For Advanced Urothelial Cancer
Further details of Merck KGaA/Pfizer-funded JAVELIN Bladder 100 study presented at this year’s ASCO confirm avelumab’s survival benefit when used as front-line maintenance therapy in patients with advanced urothelial cancer that has not progressed following initial chemotherapy.